%0 Journal Article %T Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %D 2011 %\ 02/01/2011 %V 12 %N 2 %P 487-490 %! Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer %K Irinotecan %K nedaplatin %K Chemotherapy %K small cell lung cancer %R %X Purpose: We conducted a phase II study of combination chemotherapy with irinotecan (CPT-11) andnedaplatin (NDP), (INP regimen), to determine the effects and toxicities in patients with extensive stage smallcell lung cancer (SCLC). Methods: From March 2005 to December 2010, 60 patients with histologically orcytologically confirmed extensive SCLC were enrolled into this study. All received treatment CPT-11 at a doseof 60mg/m2 on days 1 and 8, and NDP 20mg/m2 on days1-5, every 3-4 weeks as a cycle. Patients were treateduntil tumor progression or unacceptable toxicity. Results: Main toxicities included: myelosuppression, nausea orvomiting, diarrhea, elevation of alanine aminotransferase,and bilirubin. No treatment related death occurred inthis study. Thirteen patients had complete response, forty-two had partial response, three remained stable, andtwo had progressive disease. Median progression-free survival was 13 months (95% confidence interval: 9-17)and median overall survival was 22 months (95% confidence interval: 19-25). Conclusion: INP is an effectiveand well tolerated regimen for treatment of extensive staged SCLC. %U https://journal.waocp.org/article_25560_f769e493be1f22e8acf7c0f4ffc330eb.pdf